Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
The market opportunities in the PD-1 Resistant Head and Neck Cancer sector include the rising need for salvage therapies due to resistance to standard treatments, the proliferation of next-gen ...
In attempt to assess treatment patterns in advanced gastric cancer across racial and ethnic groups throughout the U.S., ...
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...
7don MSN
A new nanorobot designed to improve immune cell recognition could help treat colorectal cancer
Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...
Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results